Anti-cancer drugs Flashcards
6 classes of anticancer drugs
- alkylating drugs
- platinating drugs
- anti-metabolites
- cytotoxic antibodies
- mitotic inhibitors
- topoisomerase inhibitors
alkylating drug examples (2)
cyclophosphamide
chlorambucil
alkylating drug MOA
- reactive alkyl group forms covalent bonds with DNA, crosslinking it (rigid)
- causes DNA breaks
- disrupts DNA replication and transcription
platinating drug examples (2)
(-platin)
cisplatin (!!contradindicated with creatinine clearance <60ml/min)
carboplatin
platinating drug MOA
- acts as alkylating drugs
- forms covalent bonds with DNA, crosslinking it and causes DNA breaks
- disrupts DNA replication & transcription
anti-metabolites examples (2)
methotrexate (MTX)
5-fluoruoracil (5-FU)
anti-metabolites MOA + clinical indications
methotrexate (MTX): inhibits dihydrofolate reductase needed to recycle folate⇒ prevents thymidine monophosphate synthesis
- clinical indication: variety of tumours eg breast cancer/lymphoma
5-fluorouracil (5-FU): inhibits thymidylate synthase, gets misincorporated into DNA & RNA
- clinical indication: colorectal cancer
cytotoxic antibodies examples (3)
“-RUBICIN”
anthracyclines e.g. doxorubicin, daunorubicin, epirubicin
cytotoxic antibodies MOA (4)
- inhibits RNA/DNA synthesis by intercalating base pairs, prevents DNA replication
- create Fe mediated free O2 radicals that cause DNA damage
- inhibits topoisomerase 2
- alters membrane fluidity & ion transport
mitotic inhibitors examples (3)
(-TAXEL)
paclitaxel
docetaxel
vinblastine
mitotic inhibitors MOA
- bind to beta subunit of tubulin, disrupting formation of microtubules
- vinblastine bind to polymerizing end to prevent elongation of microtubule
- paclitaxel stabilize microtubules to prevent shortening
topoisomerase inhibitors examples (3)
type 1: -TECAN
topotecan
irinotecan
type 2: etoposide
topoisomerase MOA
inhibits type 1/2 topoisomerase, intereferes with transcription & replication of DNA
phase specific drugs (3)
- anti-metabolites
- cytotoxic antibiotics
- mitotic inhibitors
phase non-specific drugs (3)
- alkylating drugs
- platinating drugs
- topoisomerase inhibitors